Costs and Benefits of Green Roof Types for Cities and Building Owners

Increasing urbanization and the effects of climate change will bring new challenges for cities, such as energy saving and supply of renewable energy, preventing urban heat islands and water retention to deal with more frequent downpours. A major urban surface, the surface of roofs, is nowadays hardly exploited and could be used to make cities more ‘future proof’ or resilient. Many Dutch municipalities have become aware that the use of green roofs as opposed to bituminous roofs positively contributes to these challenges and are stimulating building-owners to retrofit their building with green roofs. This study aims at comparing costs and benefits of roof types, focused on green roofs (intensive and extensive) both on building- and city scale. Core question is the balance between costs and benefits for both scales, given varying local conditions. Which policy measures might be needed in the future in order to apply green roofs strategically in regard to local demands? To answer this question the balance of costs and benefits of green roofs is divided into a public and an individual part. Both balances use a strengths, weaknesses, opportunities and threats framework to determine the chance of success for the application of green roofs, considering that the balance for green roofs on an individual scale influences the balance on a public scale. The outcome of this combined analyses in the conclusion verifies that a non-committal policy for green roofs is not an effective way to prepare the city sufficiently for future climate changes

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

Costs and benefits of green roof types for cities and building owners

Increasing urbanization and the effects of climate change will bring new challenges for cities, such as energy saving and supply of renewable energy, preventing urban heat islands and water retention to deal with more frequent downpours. A major urban surface, the surface of roofs, is nowadays hardly exploited and could be used to make cities more ‘future proof’ or resilient. Many Dutch municipalities have become aware that the use of green roofs as opposed to bituminous roofs positively contributes to these challenges and are stimulating building-owners to retrofit their building with green roofs. This study aims at comparing costs and benefits of roof types, focused on green roofs (intensive and extensive) both on building- and city scale. Core question is the balance between costs and benefits for both scales, given varying local conditions. Which policy measures might be needed in the future in order to apply green roofs strategically in regard to local demands? To answer this question the balance of costs and benefits of green roofs is divided into a public and an individual part. Both balances use a strengths, weaknesses, opportunities and threats framework to determine the chance of success for the application of green roofs, considering that the balance for green roofs on an individual scale influences the balance on a public scale. The outcome of this combined analyses in the conclusion verifies that a responsible policy and a local approach towards green roofs is necessary to prepare the city sufficiently for future climate changes. http://dx.doi.org/10.13044/j.sdewes.d6.022

2023 EULAR classification criteria for hand osteoarthritis.

The objective of this study is to develop classification criteria for overall hand osteoarthritis (OA), interphalangeal OA and thumb base OA based on self-reported data and radiographic features. The classification criteria sets were developed in three phases. In phase 1, we identified criteria that discriminated hand OA from controls. In phase 2, we used a consensus-based decision analysis approach to derive a clinician-based evaluation of the relative importance of the criteria. In phase 3, we refined the scoring system, determined the cut-offs for disease classification and compared the sensitivity and specificity of the European Alliance of Associations for Rheumatology (EULAR) criteria with the 1990 American College of Rheumatology (ACR) criteria. In persons with hand symptoms and no other disease (including psoriasis) or acute injury that can explain the hand symptoms (mandatory criteria), hand OA can be classified based on age, duration of morning stiffness, number of joints with osteophytes and joint space narrowing, and concordance between symptoms and radiographic findings. Using a sum of scores based on each diagnostic element, overall hand OA can be classified if a person achieves 9 or more points on a 0-15 scale. The cut-off for interphalangeal OA and thumb base OA is 8 points. While the EULAR criteria demonstrated better sensitivity than the ACR criteria in the phase 1 data set, the performance of the two criteria sets was similar in two external cohorts. International experts developed the EULAR criteria to classify overall hand OA, interphalangeal OA and thumb base OA in clinical studies using a rigorous methodology. [Abstract copyright: © European Alliance of Associations for Rheumatology, EULAR 2024. Re-use permitted under CC BY-NC-ND. No commercial re-use. No derivatives. See rights and permissions. Published by BMJ on behalf of EULAR.”.